CannaPharmaRX Statistics
Total Valuation
CannaPharmaRX has a market cap or net worth of 2.76 million. The enterprise value is 23.40 million.
| Market Cap | 2.76M |
| Enterprise Value | 23.40M |
Important Dates
The next estimated earnings date is Friday, April 10, 2026.
| Earnings Date | Apr 10, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
CannaPharmaRX has 656.27 million shares outstanding. The number of shares has increased by 20.68% in one year.
| Current Share Class | 656.27M |
| Shares Outstanding | 656.27M |
| Shares Change (YoY) | +20.68% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 3.81% |
| Owned by Institutions (%) | n/a |
| Float | 607.90M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.62 |
| PB Ratio | -0.12 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -3.20 |
| EV / Sales | 13.72 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.05
| Current Ratio | 0.05 |
| Quick Ratio | 0.02 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -1.73 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -21.23% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | 23.46% |
| Revenue Per Employee | 65,603 |
| Profits Per Employee | -281,642 |
| Employee Count | 26 |
| Asset Turnover | 0.15 |
| Inventory Turnover | 4.78 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -50.00% in the last 52 weeks. The beta is -1,740.27, so CannaPharmaRX's price volatility has been lower than the market average.
| Beta (5Y) | -1,740.27 |
| 52-Week Price Change | -50.00% |
| 50-Day Moving Average | 0.00 |
| 200-Day Moving Average | 0.00 |
| Relative Strength Index (RSI) | 40.15 |
| Average Volume (20 Days) | 267,385 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.01 |
Income Statement
In the last 12 months, CannaPharmaRX had revenue of 1.71 million and -7.32 million in losses. Loss per share was -0.01.
| Revenue | 1.71M |
| Gross Profit | -3.28M |
| Operating Income | -3.96M |
| Pretax Income | -7.32M |
| Net Income | -7.32M |
| EBITDA | n/a |
| EBIT | -3.96M |
| Loss Per Share | -0.01 |
Balance Sheet
The company has 927 in cash and 20.02 million in debt, with a net cash position of -20.02 million or -0.03 per share.
| Cash & Cash Equivalents | 927 |
| Total Debt | 20.02M |
| Net Cash | -20.02M |
| Net Cash Per Share | -0.03 |
| Equity (Book Value) | -22.52M |
| Book Value Per Share | -0.04 |
| Working Capital | -27.01M |
Cash Flow
| Operating Cash Flow | -2.03M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | -192.09% |
| Operating Margin | -231.95% |
| Pretax Margin | -429.32% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | -231.95% |
| FCF Margin | n/a |
Dividends & Yields
CannaPharmaRX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -20.68% |
| Shareholder Yield | -20.68% |
| Earnings Yield | -265.67% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
CannaPharmaRX has an Altman Z-Score of -16.33 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -16.33 |
| Piotroski F-Score | 3 |